Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,207 public trials 1,003 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Active, Not Recruiting

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

NCT04379635

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Peoples Hospital Beijing, Beijing Municipality, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Xuanwu Hospital Capital Medical University Beijing, Beijing Municipality, China
View all 44 locations
View Trial Details
Active, Not Recruiting

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265

Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • Norton Cancer Institute - Audubon Louisville, Kentucky, United States
  • New Mexico Oncology Hematology Consultants, Ltd. Albuquerque, New Mexico, United States
  • Ascension Seton Infusion Center Austin, Texas, United States
  • Centro de Endocrinologia y Diabetes Dr. Raul A. Gutman SRL Buenos Aires, Argentina
View all 147 locations
View Trial Details
Active, Not Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

NCT05456867

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site Arkhangelsk, Russia
  • Research Site Chelyabinsk, Russia
  • Research Site Grozny, Russia
  • Research Site Irkutsk, Russia
View all 22 locations
View Trial Details
Active, Not Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations
  • ArriVent Investigative Site Prescott, Arizona, United States
  • ArriVent Investigative Site Sacramento, California, United States
  • ArriVent Investigative Site Whittier, California, United States
  • ArriVent Investigative Site Celebration, Florida, United States
View all 42 locations
View Trial Details

Related conditions